New agent approved for late-onset Pompe disease

Article

FDA has approved alglucosidase for patients aged 8 years and older for the treatment of late-onset Pompe disease.

FDA has approved alglucosidase alfa (Lumizyme, Genzyme) for patients aged 8 years and older for the treatment of late-onset (noninfantile) Pompe disease.

The agent was approved with a risk evaluation and mitigation strategy and will be available only through a restricted distribution system. The product labeling will also contain a boxed warning regarding an increased risk of anaphylaxis and severe allergic and immune-mediated reactions.

The approval of this agent was based on a clinical study in 90 patients aged 10 to 70 years with late-onset Pompe disease. In this study, the most common adverse events included infusion-related reactions.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
David Brousseau, MD, highlights impact of timely opioid dosing in pediatric sickle cell pain
Richard Bermudes, MD, on screen-related addictions and youth mental health
© 2025 MJH Life Sciences

All rights reserved.